• Assess degree and manifestations of anxiety and mental status (orientation, mood, behavior) prior to and periodically during therapy.

• Assess patient for drowsiness, light-headedness, and dizziness. These symptoms usually disappear as therapy progresses. Dose should be reduced if these symptoms persist.

• Geri: Assess CNS effects and risk of falls. Institute falls prevention strategies.

• Prolonged high-dose therapy may lead to psychological or physical dependence. Risk is greater in patients taking >4 mg/day. Restrict the amount of drug available to patient. Assess regularly for continued need for treatment.

• Monitor CBC and liver and renal function periodically during long-term therapy. May cause ↓ hematocrit and neutropenia.

• Flumazenil is the antidote for alprazolam toxicity or overdose. (Flumazenil may induce seizures in patients with a history of seizures disorder or who are on tricyclic antidepressants").